Bisolvon® | boehringer-ingelheim.in

lorem

Information for...

Patients & Carers Health Care Professional in the US Health Care Professional outside the US Journalists Jobseekers

NEWS

Pharma industry’s digital maturity has accelerated with the adoption of digital engagement channels

Read more on Pharma industry’s digital maturity has accelerated with the adoption of digital engagement channels
NEWS

People Matters Rapid Fire with Oliver Sluke

Read more on People Matters Rapid Fire with Oliver Sluke
PRESS RELEASE 26 May 2021 at 10:00

Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine

Read more on Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine
PRESS RELEASE 25 Mar 2021 at 05:00

Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management

Read more on Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management
DOWNLOAD PDF (431.14 KB)

Notice of AGM 2020

View PDFof Notice of AGM 2020
DOWNLOAD PDF (1.78 MB)

Signed Financials FY 2019-20

View PDFof Signed Financials FY 2019-20
PRESS RELEASE 31 Aug 2020 at 08:00

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults

Read more on Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults
PRESS RELEASE 18 Aug 2020 at 10:00

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Read more on Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
NEWS

Emotional Bonds—Protected with Complete Care!

Read more on Emotional Bonds—Protected with Complete Care!
PRESS RELEASE 31 Jul 2020 at 08:25

Boehringer Ingelheim launches NexGard® and Broadline® in India for comprehensive parasite control in companion animals

Read more on Boehringer Ingelheim launches NexGard® and Broadline® in India for comprehensive parasite control in companion animals
PRESS RELEASE 31 Jul 2020 at 08:00

Empagliflozin meets primary endpoint in Phase III heart failure trial

Read more on Empagliflozin meets primary endpoint in Phase III heart failure trial
NEWS

India should focus on healthcare innovation and access post-COVID-19

Read more on India should focus on healthcare innovation and access post-COVID-19
PRESS RELEASE 30 Jun 2020 at 10:00

Boehringer Ingelheim and Cipla forge partnership to co-market three oral anti-diabetic drugs

Read more on Boehringer Ingelheim and Cipla forge partnership to co-market three oral anti-diabetic drugs
PRESS RELEASE 22 May 2020 at 18:44

Drugs Controller General (India) approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Read more on Drugs Controller General (India) approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)
NEWS

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Read more on Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
NEWS

Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

Read more on Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio
NEWS

Boehringer Ingelheim expands immuno-oncology portfolio by acquiring Northern Biologics’ preclinical cancer antibody pipeline

Read more on Boehringer Ingelheim expands immuno-oncology portfolio by acquiring Northern Biologics’ preclinical cancer antibody pipeline
NEWS

BoehringerIngelheim, CDR-Life collaborate to develop antibody fragment-based therapeutics for geographic atrophy

Read more on BoehringerIngelheim, CDR-Life collaborate to develop antibody fragment-based therapeutics for geographic atrophy
NEWS

Boehringer Ingelheim and CDR-Life to develop Antibody Fragment-based Therapeutics for Geographic Atrophy

Read more on Boehringer Ingelheim and CDR-Life to develop Antibody Fragment-based Therapeutics for Geographic Atrophy
NEWS

Boehringer Ingelheim expanding immuno-oncology portfolio

Read more on Boehringer Ingelheim expanding immuno-oncology portfolio